Literature DB >> 33435899

Characterization of bone metabolism in hungarian psoriatic arthritis patients: a case-control study.

Zsófia Pethő1, Edit Kalina2, Zoltán Pap3, Katalin Hodosi4, Rebeka Falcsik4, Ádám Balogh5, Zoltán Szekanecz4, Harjit Pal Bhattoa6.   

Abstract

BACKGROUND: Skeletal manifestations are predominant in psoriatic arthritis (PsA). The aim of this cross-sectional, case-control study is the complex assessment of areal and volumetric bone mineral density (BMD), fracture risk, vitamin D status and bone turnover markers, and its association with disease-related variables.
METHODS: Lumbar spine (L1-L4) and femoral neck (FN) areal, and distal radius (DR) volumetric BMD, 10-year probability of major and hip osteoporotic fracture as assessed by the fracture risk assessment (FRAX) tool, markers of bone metabolism and disease activity were assessed.
RESULTS: Upon comparison of the disease and age- and sex-matched control groups, there was a statistically significant difference in FN areal (0.952 (0.607-1.292) g/cm2 vs. 1.016 (0.760-1.550) g/cm2; p = 0.001) and DR total volumetric (284.3 (138.9-470.3) mg/cm3 vs. 367.0 (287.0-412.0) mg/cm3; p < 0.001) BMD, 10 year probability for major osteoporotic (3.7% (0.7-32%) vs. 2.6% (0-17.5%); p = 0.003) and hip (0.4% (0-16%) vs. 0.05% (0-6.1%); p = 0.002) fracture and 25-hydroxyvitamin D status (47.5 (10-120) nmol/L vs. 64 (10-137; p < 0.001) nmol/L). As compared to areal assessment, volumetric BMD measurements identified a significantly higher number of patients with low bone mineral density (T-Score ≤ - 1.00) (34% vs. 88%, p < 0.001). Upon multiple linear regression analysis, disease activity score, as determined by DAS28 assessment, was an independent predictor of 10-year probability for major osteoporotic fracture (B (95%CI) = 1.351 (0.379-2.323); p = 0.007).
CONCLUSION: In the studied PsA cohort, disease activity was an independent predictor of 10-year probability for a major osteoporotic fracture, and complemented assessment of volumetric and areal BMD assured better efficacy at identifying those with low bone mineral density.

Entities:  

Keywords:  Areal and volumetric BMD; Bone metabolism; Disease activity; FRAX; Psoriatic arthritis

Mesh:

Year:  2021        PMID: 33435899      PMCID: PMC7805054          DOI: 10.1186/s12891-021-03952-z

Source DB:  PubMed          Journal:  BMC Musculoskelet Disord        ISSN: 1471-2474            Impact factor:   2.362


  49 in total

1.  A comparison of bone mineral density in Indians with psoriatic polyarthritis and healthy Indian volunteers.

Authors:  K Dheda; B Cassim; N Patel; G M Mody
Journal:  Clin Rheumatol       Date:  2003-12-16       Impact factor: 2.980

2.  Diagnostic tests: the erythrocyte sedimentation rate range and limitations of the technique.

Authors:  A WESTERGREN
Journal:  Triangle       Date:  1957-03

Review 3.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

4.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

5.  Estimates of optimal vitamin D status.

Authors:  Bess Dawson-Hughes; Robert P Heaney; Michael F Holick; Paul Lips; Pierre J Meunier; Reinhold Vieth
Journal:  Osteoporos Int       Date:  2005-03-18       Impact factor: 4.507

6.  Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry.

Authors:  Soumya M Reddy; Allen P Anandarajah; Mark C Fisher; Philip J Mease; Jeffrey D Greenberg; Joel M Kremer; George Reed; Rui Chen; Susan Messing; Kimberly Kaukeinen; Christopher T Ritchlin
Journal:  J Rheumatol       Date:  2010-09-15       Impact factor: 4.666

7.  Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.

Authors:  Agnes Szentpetery; Malachi J McKenna; Barbara F Murray; Chin Teck Ng; Jennifer J Brady; Michelle Morrin; Bea Radovits; Douglas J Veale; Oliver Fitzgerald
Journal:  J Rheumatol       Date:  2013-03-01       Impact factor: 4.666

8.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.

Authors:  S Garrett; T Jenkinson; L G Kennedy; H Whitelock; P Gaisford; A Calin
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

9.  Psoriatic arthritis (PSA)--an analysis of 220 patients.

Authors:  D D Gladman; R Shuckett; M L Russell; J C Thorne; R K Schachter
Journal:  Q J Med       Date:  1987-02

Review 10.  Prevalence and risk factors of low bone mineral density in psoriatic arthritis: A systematic review.

Authors:  Shelly Chandran; Ali Aldei; Sindhu R Johnson; Angela M Cheung; David Salonen; Dafna D Gladman
Journal:  Semin Arthritis Rheum       Date:  2016-05-25       Impact factor: 5.532

View more
  1 in total

Review 1.  Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.

Authors:  Harjit P Bhattoa; Zoltán Szekanecz; Boglárka Soós; Ágnes Szentpétery; Hennie G Raterman; Willem F Lems
Journal:  Nat Rev Rheumatol       Date:  2022-03-10       Impact factor: 20.543

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.